Signal profiling of the $\beta_1$AR reveals coupling to novel signalling pathways and distinct phenotypic responses mediated by $\beta_1$AR and $\beta_2$AR

Viktoriya Lukasheva1,7, Dominic Devost2,7, Christian Le Gouill1,7, Yoon Namkung3, Ryan D. Martin2, Jean-Michel Longpré6, Mohammad Amraei1, Yuji Shinjo6, Mireille Hogue1, Monique Lagacé3, Billy Breton7, Junken Aoki6, Jason C. Tanny2, Stéphane A. Laporte2,3, Graciela Pineyro5, Asuka Inoue6, Michel Bouvier1 & Terence E. Hébert2

A comprehensive understanding of signalling downstream of GPCRs requires a broad approach to capture novel signalling modalities in addition to established pathways. Here, using an array of sixteen validated BRET-based biosensors, we analyzed the ability of seven different $\beta$-adrenergic ligands to engage five distinct signalling pathways downstream of the $\beta_1$-adrenergic receptor ($\beta_1$AR). In addition to generating signalling signatures and capturing functional selectivity for the different ligands toward these pathways, we also revealed coupling to signalling pathways that have not previously been ascribed to the $\beta$AR. These include coupling to $G_s$ and $G_{12}$ pathways. The signalling cascade linking the $\beta_1$AR to calcium mobilization was also characterized using a combination of BRET-based biosensors and CRISPR-engineered HEK 293 cells lacking the $G_\alpha_s$ subunit or with pharmacological or genetically engineered pathway inhibitors. We show that both $G_s$ and $G_{12}$ are required for the full calcium response. Our work highlights the power of combining signal profiling with genome editing approaches to capture the full complement of GPCR signalling activities in a given cell type and to probe their underlying mechanisms.

Recent studies have established that GPCRs engage multiple signalling pathways and that ligands can discriminate between these pathways, which is now defined as functional selectivity or biased agonism1–4. Such effects have been characterized by examining the production of individual second messengers or more recently direct examination of proximal effector activation. Identification of signalling pathways beyond canonical effector systems has demonstrated the need to cast a broader net in studying signalling outcomes downstream of a given receptor. One such example is the recent recognition that, in addition to cAMP production, $\beta$-arrestin recruitment and ERK1/2 activation, the $\beta_2$-adrenergic receptor ($\beta_2$AR) can also promote calcium mobilization in a ligand-selective manner5,6. However, relatively little is known about functional selectivity for the $\beta_1$AR. Although several papers have described functional selectivity for $\beta_1$AR ligands7,8, a more comprehensive analysis of distinct pathways operating in living cells and the elaboration of a signalling signature is still lacking. Certain $\beta$AR antagonists, likely acting on cardiac $\beta_1$AR, can activate a cardioprotective pathway involving $\beta$-arrestin signalling. Notably,
alprenolol and carvedilol both acted as agonists for this pathway in a manner similar to clinically used agonists such as dobutamine and isoproterenol. Thus carvedilol and alprenolol may be agonists for β1AR signalling pathways which might underlie their cardioprotective mechanisms in heart failure, in contrast to numerous other βAR antagonists without such pleiotropic activity. Carvedilol is known to activate ERK1/2 via a pathway involving β-arrestin. These observations argue that such functional selectivity is worth exploring further for both receptors which may have clinical impact in a number of diseases.

Historically, most GPCRs have been defined as being coupled to a primary heterotrimer G protein partner. However, it is clear that such definitions are oversimplifications of the actual wiring of receptors into multiple signalling pathways. Therefore, to generate a more global understanding of the repertoire of signalling pathways that can be engaged by a given receptor, and of the possible implications of signalling diversity generated by different ligands, a broader approach taking into account multiple GPCR effectors and downstream signalling cascades is needed. Toward that end, we present here an integrated platform of BRET-based biosensors detecting both proximal and distal outputs downstream of the β1AR. We combine this with CRISPR/Cas9 genome editing and genetically engineered dominant negative approaches to target G proteins to examine the functional consequences of removing individual G proteins on signalling outcomes.

BRET-based biosensors have become a convenient and robust method for characterizing both canonical and novel signalling pathways modulated by GPCRs. These biosensors have distinct designs that allow detection of intermolecular interactions between proteins, intramolecular structural reorganization resulting from protein partners, and ligand or second messenger binding. We show that the combination of such biosensors, including two specifically developed for the present study, with genome editing approaches facilitates detection of new signalling pathways downstream of a given receptor as well as their functional consequences.

**Results**

**General approach.** The purpose of the study was to obtain a broad profiling of the signalling activity of the β1-adrenergic receptor to generate a more comprehensive map of its signalling potential. We chose the β1AR as an example of an extensively studied GPCR to explore the possibility that, in addition to well-characterized signalling pathways which have been studied for many decades (i.e.: Gs/cAMP and β-arrestin), new pathways might also be revealed (Supplementary Fig. S1). To explore the potential pleotropic receptor signalling, seven β-adrenergic ligands were tested across a panel of identified signalling cascades. For this purpose, we used a variety of BRET-based sensors that allowed us to monitor 10 different G protein subtypes (including at least one from each of the 4 Go subunit classes), β-arrestin2, and the activity of 4 effectors downstream of engaged G proteins. To probe the functional significance of the newly identified β-adrenergic-activated signalling pathways, we combined the use of the biosensors with a CRISPR-Cas9-generated cell line lacking Goα1, the cognate G protein subtypes engaged by β1AR as well as a novel engineered dominant negative construct selectively inhibiting Goα12/13.

**G protein pathways engaged by the β1AR.** In order to assess which G protein subtypes were activated by the β1AR, we used a panel of biosensors designed to capture the activation state of the heterotrimer by measuring the physical separation of Goα and Gβγ subunits via BRET. Figure 1 shows BRET titration curves for 10 different Go subunits, indicating that the β1AR agonist isoproterenol leads to a robust activation of Goα, G12 and G13, as measured by a decrease in BRET. Smaller decreases in BRET in response to isoproterenol were also observed for other G proteins (G12, Gααα and Gαβ). No responses were observed for Gαq, G11, or G16. The lack of activation of different G protein isoforms did not result from insufficient biosensor sensitivity since robust responses were detected for the D2 dopamine receptor toward all Go subtypes (Supplementary Fig. S2), for TPα receptors toward both G12 and G13 (Supplementary Fig. S3a,c) as well as for other GPCRs toward G12, G13 and G16. To further characterize the activation of these G proteins and their downstream effector pathways by a panel of βAR ligands, full concentration-response curves and kinetic measurements were obtained using both the G protein sensors described above and biosensors detecting downstream events representative for each of these pathways.

**Gs signalling.** To probe the Gs signalling pathway, an EPAC biosensor sensitive to cAMP levels was used in conjunction with the Gs activation biosensor (Fig. 2a,b). Similar activation kinetics were detected using both biosensors (Fig. 2c,d) and the effects of both full and partial agonists were revealed by the concentration-response curves (Fig. 2e,f). A general pattern of concordance for both biosensors (Supplementary Tables S1 and S2) was observed with respect to efficacy and potency, although the differences between full and partial agonists were reduced when using the EPAC biosensor, consistent with the notion of signal amplification at the level of cAMP production.

**Gq signalling.** For each of the canonical PTX-sensitive Gi family members (G11, Gααα and Gαβ, Fig. 3a), concentration-response curves were generated to further characterize the weak activation detected for some of these isoforms in BRET titration experiments. Reproducible kinetic responses and concentration/response curves could only be obtained for G11 (Fig. 3b,c, Supplementary Tables S1, S2). Interestingly, only three agonists (isoproterenol, epinephrine and norepinephrine) could elicit responses from G12, suggesting more efficient coupling to G12. Of note, isothearine and indacaterol, which were close to full agonist on Gs activation and cAMP production could not evoke any Gi activation. The fact that we only detected G11 is not because this biosensor is more sensitive than those for other Gi family members, as we could detect a more robust response for G11 than G12 for the D2-dopamine receptor which can activate all Gi subfamily members (Supplementary Fig. S2). Although not previously reported for the β1AR, previous studies have also demonstrated coupling of the β1AR to Gq using conventional assays and we could also detect β1AR coupling to G12 using the BRET-based sensor (Fig. 3d,e).
**Figure 1. Identification of the Gα protein involved in β₁AR signalling.** (a) Schematic representation of the Gα-Rluc/Gγ-GFP biosensor used to identify the Gα proteins involved in β₁AR signalling. (b–k) HA-β₁AR HEK 293 stable cell lines were transfected with a constant amount of Gα-Rluc (BRET donor) and untagged Gβ₁, along with increasing amounts of Gγ₁-GFP construct (BRET acceptor). Cells were stimulated (red curves) or not (black curves) with 1μM isoproterenol and BRET values collected. NetBRET values were calculated by subtracting the background BRET signal detected in cells expressing the Rluc-fused constructs alone (donor-Rluc) from the BRET values obtained in cells expressing the energy donor and acceptor (donor-Rluc and acceptor-GFP). BRET titration curves were generated for 10 different Gα subunits: Gα₁ (b), Gα₆ (c), Gα₁₂ (d), Gα₁₅ (e), Gα₁₃ (f), Gα₁₂ (g), Gα₁₁ (h), Gα₁₅ (i), and Gα₁₅ (j) and Gα₁₅ (k). Values represent mean ± SEM of 3 independent experiments performed in triplicate. Responses for Gα₁₅, Gα₁₅, Gα₁₁, and Gα₁₅ were further analyzed in subsequent sections.
Gz signalling. Gz is an atypical member of the Gi family as it is insensitive to pertussis toxin. We next investigated if this G protein could be activated by the β1AR. Our BRET-based biosensor (Fig. 4a) detected robust time- and concentration-dependent activation of Gz by the β1AR (Fig. 4b,d). The concentration-response curves in Fig. 4d show that, in addition to the three full agonists for Gs, indacaterol also acted as a weak partial agonist for Gz. The lack of detection of the effects of other partial agonists was not caused by differential dynamic windows in each assay as isoproterenol responses were similar in both the Gs and Gz sensors (compare Fig. 1b with Fig. 1i). As Gz coupling has never previously been documented for any βAR subtype, we also examined the ability of the β2AR to engage Gz. The kinetics of activation in response to isoproterenol were similar for both receptor subtypes (Fig. 4b,c). Further, as expected, the rank order of potency of the ligands was distinct for each receptor subtype, generally reflecting their relative affinities for the two receptors (Fig. 4d,e). However, one notable exception was that despite its characterization as a β2AR-selective ligand, indacaterol only produced a response in the β1AR, indicating that selectivity also depends on the signalling pathway examined; a further manifestation of functional selectivity. A similar effect was observed for isoetharine, activating Gs through both β1- and β2AR (albeit with lower potency for the β1AR), but only resulting in Gz coupling for the β2AR (Fig. 4e).

G12 signalling. Another novel feature of βAR signalling captured by our biosensor panel was the activation of G12 (Fig. 5a,c,e,g) with no detectable activation of G13 (compare Fig. 1d,e). A previous report showed a similar ability of GPR35 to discriminate between G12 and G13. The lack of activation of G13 by the β2AR did not result from lower sensitivity of the biosensor as we could readily detect its activation by a known activator, the TPOα receptor (TPoαR, Supplementary Fig. S3a,c). To confirm and further characterize G12 activation, an additional
Figure 3. Go12-induced activation by the β1AR and β2AR. (a) Schematic representation of the Go12-Rluc/γ11-GFP biosensor used to study the Goi induced β1AR and β2AR signalling. HEK 293 cells were transfected with (b–e) Go12-Rluc, Gγ11-GFP and untagged Gβ1, along with (b–c,e) β1AR or (d–e) β2AR. (b,d) Kinetics curves represent time course of Go12 activation by (b) β1AR (vehicle and isoproterenol, n=3) or (d) β2AR (vehicle and isoproterenol, n=3) expressed as absolute BRET ratios. (c) Concentration–responses curves for Go12 activation following β1AR activation by indicated ligands. (e) Concentration–responses curves for Go12 activation following isoproterenol-induced activation of β1AR or β2AR (n=2). Data were normalized to maximal isoproterenol response, which was taken as 100%, and are expressed as mean ± SEM values. Detail (c) of the number of experiments, maximal responses, pEC50 values and statistical comparisons of curve parameters for different ligands are provided in Supplementary Tables S1 and S2.

assay monitoring downstream engagement of p115-RhoGEF was designed (Fig. 5b) and again validated using TMRh2R (Supplementary Fig. S3b,d). This biosensor monitors recruitment of the rGβ1 γ domain of the Go12/13 effector, p115-RhoGEF, directly to Goi by monitoring BRET between Go12-Rluc and p115-RhoGEF-GFP10. The expression of the biosensor components did not affect cell surface receptor expression (Supplementary Fig. S4a,b). Rapid Go12 activation kinetics and recruitment of p115-RhoGEF were noted in response to isoproteneol (Fig. 5d,f). The kinetics of the two biosensors were quite different. It is difficult to make direct kinetic comparisons between biosensors based on different designs. In the case of Fig. 5c, the G12 activation biosensor is based on dissociation of Goi from Gβ1 γ whereas the biosensor for RhoGEF is based on recruitment of a subdomain of p115-RhoGEF to the Goi (Fig. 5d). The dynamics of such interactions are most likely different and possibly explain the difference in the kinetics observed. The other compounds tested displayed similar potencies and efficacies for either of the two G12 pathway biosensors, with the exception of the weak partial agonist isoetharine, where activity could only be detected for the Go12/G12/G12 sensor (compare Fig. 5e,f). Compounds had similar rank order of potencies and efficacies as those observed for Goi.

As for Goi coupling discussed above, engagement of Goi had never been previously described for any βAR subtype. Therefore, the ability of the β2AR to activate this pathway was also examined. The β2AR was also capable
of activating G12 with potencies that were similar between the two receptors (Fig. 5g). To further characterize
the downstream consequences of the engagement of Gα12 by the β1AR, we next assessed activation of the Rho
pathway, a known downstream effector of G12. Recruitment of PKN to the plasma membrane was measured
using an ebBRET17 biosensor based on PKN translocation to the plasma membrane upon Rho activation. This
sensor monitors RlucII-tagged PKN (Rluc-PKN) density at the plasma membrane, which is labelled with a BRET
acceptor, Renilla reniformis GFP (rGFP-CAAX, Fig. 6a). TPαR, a known activator of the G12/Rho/PKN path-
way35–37, was used to validate this biosensor. As shown in Fig. 6c, agonist-mediated activation of TPαR led to an
increased BRET signal, reflecting membrane recruitment of PKN. This response was blocked by the TPαR antag-
onist, SQ 29548. Consistent with the ability of this biosensor to detect Rho activity, a constitutively active mutant
form of RhoA, Q63L-RhoA38, promoted robust BRET from the PKN-based sensor (Fig. 6d). To further validate
the PKN recruitment assay as a faithful readout of G12/13 activity, we assessed the effect of co-expressing either
WT or constitutively active forms (CAM) of Gα12 or Gα13. As seen in Fig. 6e, expression of WT Gα12 and to a
greater extent of CAM Gα12 and CAM Gα13 significantly increased recruitment of PKN to the plasma membrane.
Finally, we designed a plasma membrane-targeted inhibitor of G12/13 activity by fusing the rgRGS domain of
P115-RhoGEF (p115-RGS) to the membrane anchoring CAAX domain (p115-RGS-CAAX) (Fig. 6b). As shown
in Fig. 6f, expression of p115-RGS-CAAX completely blocked the ability of U46619 to promote PKN recruit-
ment to the plasma membrane as assessed by ebBRET39. The Gq inhibitor YM254890 did not affect the response,
confirming that PKN recruitment resulted mainly from G12/13 activation. The selectivity of p115-RGS-CAAX

Figure 4. Gαz-induced activation by the β1AR and β2AR. (a) Schematic representation of the Gαz-Rluc/Gγ1-
GFP biosensor used to study the Gαz induced βAR signalling. HEK 293 cells were transfected with Gαz-Rluc,
Gγ1-GFP and untagged Gβ1, along with (b,d) β1AR or (c,e) β2AR. Kinetic curves represent time course of
Gαz activation by (b) β1AR (vehicle n = 1; isoproterenol n = 2) or (c) β2AR (vehicle and isoproterenol, n = 2)
expressed as absolute BRET ratios. Concentration-responses curves for Gαz activation following (d) β1AR or (e)
β2AR activation by indicated ligands. Data were normalized to maximal isoproterenol response, which was take
as 100%, and are expressed as mean ± SEM values. Details of the number of experiments, maximal responses,
pEC50 values and statistical comparisons of curve parameters for (d) βAR activation by different ligands are
provided in Supplementary Tables S1 and S2. For (e) β2AR activation, n = 3 for all ligands.
inhibitory action on G_{12/13} was confirmed by its lack of effect on the activation of G_{q}, G_{i2} or G_{s}-mediated cAMP production stimulated by TP_{α}R, D4R and β_{1}AR, respectively (Supplementary Fig. S5b–d). Expression of the biosensor component did not influence the cell surface receptor expression (Supplementary Fig. S4c). As shown in Fig. 6g,h, stimulation of the β_{1}AR promoted PKN recruitment to the plasma membrane that was blocked by the expression of the G_{12/13} activity dominant negative p115-RGS-CAAX, confirming engagement and activation of G_{12} by the β_{1}AR.

Figure 5. **G_{α_{12}}-induced activation by the β_{1}AR.** (a) Schematic representation of the G_{α_{12}}-Rluc/G_{γ_{1}}-GFP biosensor used to study the G_{α_{12}} induced β_{1}AR signalling. (b) Schematic representation of the G_{α_{12}}-Rluc/p115-RhoGef-GFP (p115-GFP) biosensor used to study the G_{α_{12}} induced β_{1}AR signalling. HEK 293 cells were transfected with (c,e,g) G_{α_{12}}-Rluc, G_{γ_{1}}-GFP and untagged G_{β_{1}} or with (d,f) G_{α_{12}}-Rluc, p115-GFP and untagged G_{γ_{1}} and G_{β_{1}}, along with β_{1}AR or (g) β_{2}AR. Kinetic curves represent time course of (c) G_{α_{12}} activation (vehicle and isoproterenol n = 3) or (d) G_{α_{12}}-p115 biosensor activation (vehicle n = 2, isoproterenol n = 3), expressed as absolute BRET ratio. Concentration-responses curves for (e) G_{α_{12}} activation or (f) G_{α_{12}}-p115 biosensor activation following β_{1}AR activation by indicated ligands. (g) Concentration-responses curves for G_{α_{12}} activation following isoproterenol-induced β_{1}AR or β_{2}AR stimulation (n = 6). Data were normalized to maximal isoproterenol response (100%), and are expressed as mean ± SEM values. Detail (e,f) of the number of experiments, maximal responses, pEC_{50} values and statistical comparisons of curve parameters for (e,f) β_{1}AR activation by different ligands are provided in Supplementary Tables S1 and S2.
Figure 6. **PKN-recruitment based biosensor to monitor receptor-induced activation of Rho signalling for TPαR and β1AR.** (a) Schematic representation of the PKN-recruitment based biosensor. (b) Schematic representation of the mode of action of p115-RGS-CAAX construct (P115-CAAX) as a dominant negative construct for G protein signalling. HEK 293 cells were transfected with PKN-RlucII and rGFP-CAAX along with either (c–f) HA-TPαR or (g,h) β1AR, in the presence or absence of (d) constitutively active RhoA mutant (Q63L), (e) Gα12, Gα13 or their constitutively active (CAM) versions (Gα12CA Q231L and Gα13CA Q226L) or (f-h) p115-CAAX. (c) Treatment with the TP antagonist SQ 29,548 inhibits PKN recruitment following TPαR activation by U46619. 0 ng represents the activity of endogenously expressed receptor. Data are expressed as ΔBRET signal and are the mean ± SEM (n = 3). Statistical comparisons for antagonistic effect were done using two-way ANOVA followed by post-hoc comparison with Sidak’s test. (d,e) PKN recruitment to the plasma membrane upon U46619-induced TPαR activation in the presence or absence of (d) constitutively active RhoA mutant (Q63L) or (e) Gα12, Gα13 or their CAM versions. Data are expressed as BRET signal and are mean ± SEM ((d)
Calcium signalling. Using a bioluminescent obelin calcium biosensor, we observed that similar to β2AR activation, β3AR stimulation leads to a calcium response. As shown in Fig. 7, only three of the seven ligands tested (isoproterenol, epinephrine and norepinephrine) were able to stimulate a calcium response (Fig. 7c,d). Interestingly, these three compounds were also identified as full agonists using the Gαi2, biosensor. Ligands such as isoetharine and indacaterol that were almost full agonists for the Gβ2 pathway but only weakly activated Gs12 were unable to promote significant calcium mobilization, suggesting that Gs12 could play a role in the calcium response. To test this notion, we assessed β3AR-mediated calcium mobilization in the presence or absence of the G12/13 dominant negative p115-CAAX construct. Isoproterenol-stimulated calcium mobilization through either βAR isoform (Fig. 7e) was blunted in the presence of p115-RGS-CAAX, confirming the functional relevance of G12 coupling. Again, both receptors were expressed at similar levels which was not altered by the presence of p115-CAAX (Supplementary Fig. S4d). Given that the receptor calcium responses were only partially affected by the inhibition of G12/13 signalling, we next examined potential contributions of other G proteins activated by these receptors. As shown in Fig. 7f, the isoproterenol-mediated response for either β2AR or β3AR was significantly reduced in CRISPR-Cas9-generated cells lacking Gα12, again with no change in levels of receptor expression (Supplementary Fig. S4e). Restoration of Gα12 expression in the ΔGs cells rescued β2AR and β3AR-mediated calcium influx, confirming a role for Gα12 in this response. Taken together, the data indicate that both G12/13 and Gs12 contribute to βAR-mediated calcium mobilization.

β-arrestin recruitment. Finally, we examined recruitment of β-arrestin2 to the β3AR in response to various agonists using a previously described β-arrestin biosensor (Fig. 8). Interestingly, only isoproterenol, epinephrine and norepinephrine acted as full agonists, indacaterol being a partial agonist (Fig. 8c), while isoetharine, xamoterol and salmeterol showed no β-arrestin recruitment.

Global signalling profiles. Given the granularity of the signalling profiles obtained, we analyzed the potential for functional selectivity amongst the pathways engaged by the β3AR. The operational model was used to capture signalling efficiency in the form of Log(τ/Kα) (Supplementary Fig. S6, Supplementary Table S3). The propensity of each compound to activate the pathways considered was illustrated using a radial graph format in which each of the vertices represented activity towards one of the biosensors tested. Both maximal response and the efficiency expressed as Log(τ/Kα) are shown. This analysis revealed that maximal response and efficiency profiles of isoproterenol, epinephrine or norepinephrine were practically identical for all the pathways analyzed. However, the patterns were quite different when considering the effects of isoetharine, salmeterol, indacaterol and xamoterol. These 4 compounds were partial agonists to different extents toward the Gαi2/cAMP pathway and they displayed different abilities to promote detectable activation of Gs12, Gs12, G12 and β-arrestin2. The most efficient of the four partial agonists toward Gαi2/cAMP, indacaterol, was also able to recruit β-arrestin2, and activate Gα12, and Gqi2. Isoetharine could activate G12 and Gqi2, and salmeterol and xamoterol could only activate Gi2. These different signalling profiles are illustrated in Supplementary Fig. S7 in which the relative efficiency is color-coded for each of the signalling pathways studied. Whether this reflects true functional bias or pure partial agonism towards pathways coupled to the activated receptor is difficult to unambiguously determine. When comparing the efficiency of each ligand towards the different pathways using the operational model (log(τ/Kα)), the rank order of coupling efficiency of each compound (except for xamoterol) was respected for all pathways measured (Supplementary Fig. S7). However, although indacaterol and xamoterol had similar efficiencies as epinephrine and norepinephrine to activate the Gαi2/cAMP pathways, they were much weaker than these two compounds at activating Gαi2, Gqi2, G12 or promoting the recruitment of β-arrestin2, in many cases not activating them at all. To a lesser extent, a similar comment can be made for isoetharine and salmeterol, although their efficiency to activate Gi2 and cAMP production is slightly less than norepinephrine and epinephrine. In any case, the data clearly reveals distinct signalling profiles for the different ligands that translate into distinct cellular outputs.

Discussion
The β3AR was chosen here as prototypical GPCR where functional selectivity and biased signalling has been examined, albeit to a limited extent. In previous studies, different ligands were reported to act in a biased fashion toward either ERK1/2 MAPK or adenylyl cyclase signalling and, in some cases antagonists or inverse agonists for the adenylyl cyclase pathway acted as agonists for the MAPK pathway. These studies and similar ones for other GPCRs open the possibility that fine-tuning receptor-specific signalling outputs with functionally selective ligands could generate superior therapeutic options for a number of diseases by disfavouring signalling cascades associated with adverse effects without compromising beneficial pathways. To do this would first require a broader approach to the signalosome downstream of the receptors to capture the ensemble of pathways that can be engaged by any given receptor. However, in most cases, only a limited number of pathways have been
examined. In addition, comprehensive signal profiling of proximal and distal outputs can reveal novel signalling pathways downstream of a given receptor and how these pathways might interact. The approach proposed in the present study was to combine BRET-based signal profiling with genome editing and the use of pharmacological and genetically engineered inhibitors to allow a more detailed dissection of the relevant signalling architecture in a model cell type, establishing proof of principle.

**Figure 7.** Calcium response promoted by β₁AR or β₂AR activation. (a) Schematic representation of the luminescence Obelin biosensor used to detect calcium. (b) Schematic representation of the mode of action of p115-RGS-CAAX (p115-CAAX) construct as a dominant negative construct for the inhibition of G12/13 signalling. HEK 293 cells stably expressing HA-β₁AR were transfected with Obelin. (c) Kinetics of calcium response by indicated ligands (representative, isoproterenol, n = 10, other ligands n = 3) and expressed as relative luminescence units. Detail of the number of experiments, maximal responses, pEC₅₀ values and statistical comparisons of curve parameters for different ligands are provided in Supplementary Tables S1 and S2. (d) Concentration-response curves for Ca²⁺ mobilization following β₁AR activation by indicated ligands. Data were normalized to maximal isoproterenol response (100%), and expressed as mean ± SEM values. Detail of the number of experiments, maximal responses, pEC₅₀ values and statistical comparisons of curve parameters for different ligands are provided in Supplementary Tables S1 and S2. (e) HEK 293 cells were transiently transfected with β₁AR or β₂AR along with the obelin biosensor, with or without the p115-CAAX inhibitor. Data were normalized to maximal A23187 response (100%), determined from the area under the curve (AUC), and are expressed as the mean ± SEM values (n = 3). Statistical comparisons were done using two-way ANOVA followed by post-hoc comparison with Tukey’s test. (f) Parental HEK 293 or ΔGαs cells were transfected with β₁AR or β₂AR, along with obelin, with or without Gαs. Data normalization and statistical analysis were done as described in (e) (n = 3).
over G12. The implications for G12 signalling downstream of βAR activation may include cell shape changes as well as cell migration, mediated through activation of the Rho pathway.

Interestingly, we noted that both Gs and G12 seem to be involved in βAR-mediated calcium mobilization, suggesting a role in calcium signalling, beyond the well-characterized activation of voltage-gated calcium channels by βAR in excitable tissues [44–46]. βAR-mediated calcium mobilization in non-excitable HEK 293 cells was previously reported to require transactivation of the purinergic P2Y receptor through a Gs-dependent but cAMP-independent mechanism [20]. Whether G12 activation is also involved in this transactivation remains to be determined. For compounds such as isoproterenol that activated both Gs and G12, we found that the two pathways contributed to rise in cytoplasmic calcium, as cells deleted for either Gs or in which G12/13 was inhibited by the G12/13 dominant negative construct, p115-RGS-CAAX showed calcium responses significantly lower than those observed in the parental cells. Interestingly, compounds such as indacaterol, isoetharine and salmeterol that were strong partial agonists for Gs but weak partial agonist (indacaterol, isoetharine) or unable to activate G12 (salmeterol) could not generate significant calcium mobilization. This is consistent with an important role of G12 in calcium mobilization. Dominant-negative RhoA or the ROCK inhibitor Y-27632 were previously shown to block GPR55-mediated Ca²⁺ transients [47,48], consistent with a role for the G12/13 pathway in calcium responses. In a recent paper, the β1AR was proposed to couple to Gi, using DREADDs in combination with CRISPR gene deletions [39]. In theory, part of the calcium response could originate from this pathway as well. Although this cannot be excluded, this is unlikely since RNA-Seq analysis did not show detectable expression of G14 in the cells we used (Supplementary Table S4).

Another novel observation of our study is the subtype-selective coupling of β1AR to Gi family members. Although coupling to Gi had already been shown for the β2AR [30,31], our study is the first report showing that the β1AR can also couple to Gi family members. When considering the pertussis toxin-sensitive Gi isoforms, β1AR-mediated activation could only be detected for Gi2, indicating a possible selectivity among the Gi protein families. This apparent selectivity did not result from a different sensitivity of the BRET biosensors themselves, since dopamine D2R-mediated activation of Gi1 was more robust than that of Gi2 while those of Gi3,
β different pathways tested downstream of the in disease-relevant cells. Our results showed a limited functional bias for the various agonists tested among the cellularly relevant cell systems as the HEK 293 cell may not reflect important differences in signalling pathways further explored functional differences among different members of the same Gi subfamily and start to understand the evolutionary pressures that maintained these closely related subtypes.

Our data also reveal for the first-time robust coupling of both the β1- and β2AR to Gi1, a member of the Gi subfamily lacking an ADP ribosylation site, making them pertussis toxin-insensitive. This subtype has been shown to inhibit adenyl cyclase types I, V and VI40 and has been found to have a very low intrinsic GTPase activity compared to other G protein subtypes, including other Gi isoforms. It is widely expressed in many tissues and is found in high levels in the central and peripheral nervous systems as well as in the platelets. In these circulating cells, Gi knockout mice were found to display platelet aggregation at physiological concentrations of epinephrine40. The physiological implications of this Gi coupling to the βARs remain to be investigated but the possibility of a counter regulatory action on the G12-stimulated production of cAMP in tissues expressing Gi and the adenyl cyclase sensitive to this Gi subunit will be worth exploring. It should be noted that the potency of ligands to activate Gi is an order of magnitude lower than that for Gi activation, which would be consistent with a biphasic regulation of adenyl cyclase, allowing for tight regulation and possibly oscillatory behaviours.

The present paper clearly illustrates that broader profiling of signalling pathways that can be engaged by a receptor that can reveal signalling pathways that had not been anticipated before, even for receptors as well studied as the β1- and β2AR. We acknowledge that apparent differences in coupling efficacy between the β1- and β2AR could result from different expression levels, as they were not directly compared. The data also reveals that different ligands produce distinct signalling profiles leading to the activation to specific subsets of a given receptor’s repertoire. Whether these different profiles result from bona-fide biased signalling or are consequences of different level of partial agonism and different coupling strengths of the different effectors engaged is difficult to unambiguously determine at this point, especially when no bias factor can be calculated because of the absence of response for some of the pathways. Nevertheless, the selective activation of weakly coupled pathways seems to correlate with the overall relative efficacy of the compounds tested, indicating that partial agonism plays an important role in the apparent functional selectivity. However, whether the different signalling profiles result from biased signalling or partial agonism, the end result is that some ligands activate certain pathways but not others and that this is bound to have functional consequences. Many of our biosensors are based on overexpression of G protein subunits which may alter native receptor/G protein stoichiometries. An additional caveat must be considered when using gene deleted lines where rewiring of signalling pathways might occur. Resolving such issues will require a closer focus using distinct approaches.

What impact might the novel signalling pathways uncovered in the present study and the ligand-selective signalling profiles observed have on clinical indications where β-adrenergic agonists or antagonists are used will be an interesting area for further study. For this purpose, it will be critical to move biosensors into more physiologically relevant cell systems as the HEK 293 cell may not reflect important differences in signalling pathways in disease-relevant cells. Our results showed a limited functional bias for the various agonists tested among the different pathways tested downstream of the β1AR, but was able to robustly discriminate between partial and full agonists. Thus, as a homogenous platform, our approach allows a more global appreciation of the signalling profile of a given cell.

**Material and Methods**

**Cell culture and transfection.** HEK 293 and ΔGoi cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin/streptomycin at 37 °C in 5% CO2. The HA-β1AR HEK 293 stable cell line was maintained in complete medium supplemented with 1 μg/ml of puromycin. Except for Gi1 titration and concentration-response curves with β2AR, all transfections were carried out as follows: 48 h before the experiments, cells were transfected in suspension using polyethylenimine at 3:1 PEI/DNA ratio and seeded (~3 × 104 cells/well) in 96-well/plates pre-treated with poly-D-lysine. Each of the expression vectors and biosensor constructs were diluted in PBS, and the total quantity of DNA was completed to 1 μg/row with salmon sperm DNA. For Gi1 titration and concentration-response curves, stable HA-β1AR cells were plated at 9000 cells/well in a poly-ornithine treated white 96-well plate the day before transfection and were transfected using PEI (2.5 μg PEI:1 μg DNA ratio) at 150 ng total DNA (i.e. biosensor constructs, HA-β1AR vector and empty pcDNA3.1 vector) per well. 24 h post-transfection, the medium was changed. The HA-β1AR HEK 293 stable cell line was used for all β1AR experiments, except for Gi3 and Goi3, saturation curves and when experiments were done in parental and ΔGoi (ΔGoi3) cell lines, β1AR-encoding plasmid was also added in the transfection mix for all experiments, except for EPAC and obelin biosensors, where native responses were measured.

**Signalling biosensors.** G protein activation biosensors: G protein activation was measured by monitoring the separation of Goi from Gαi subunits. Cells were transiently transfected with the receptor (HA-β1AR, HA-β2AR, HA-TPAR or D2R (250–300 ng) along with the BRET-based biosensors composed of the specific Go2-Rluc (i.e. Go2α, 67RlucII (40 ng), Go2α, 94RlucII (60–100 ng), Go2α, 84RlucII (50 ng), Go2α, loopRlucI (40 ng), GFlp10-Gr-1 (200–250 ng) and stoichiometric amounts of the untagged Gαi3, subunit (100 ng)21,52, Go2a, Go2α, Go2α, 67RlucII, Go2α, 94RlucII and Go2α, 84RlucII (20–60 ng) were used to generate BRET saturation curves. However, only the Go2α biosensors give a sufficient signal above vehicle, when activated with isoproterenol, were further studied with additional ligands in kinetics and concentration-response experiments. For saturation and concentration-response experiments, BRET values were monitored 1 to 3 min after agonist addition, except for Gi3 and Gi1, where they were monitored 10 min after agonist addition.
EPAC cAMP biosensor: Another BRET-based biosensor was used to monitor changes in cytosolic cAMP was described previously. This consisted of an N-terminal GFP10 with a 5 amino acid residue (GSAGT) linker to a mutated EPAC1 (ΔΔEP; T781A; F782A) biosensor and a C-terminal-RlucII with a 5 residue linker (KLPAT). Stable HA-β1AR HEK 293 cells were transiently transfected with 50 ng of EPAC biosensor per row of a 96-well plate. For concentration-response experiments, BRET values were monitored 15 min after agonist addition.

p115RhoGEF biosensor to monitor Go13 activity: A BRET-based biosensor composed of RGS-homology (RH) domain (amino acids 1–246) of p115RhoGEF fused to GFP10 and G12-84RlucII was used to measure Go13 activity. Cells were transfected with 40 ng of G12-84RlucII, 500 ng of p115RhoGEF-GFP10 and 300 ng of receptor per row of a 96-well plate. For concentration-response experiments, BRET was monitored 2 minutes after agonist addition.

PKN biosensors to monitor Rho activation: Upon receptor stimulation, activated G proteins promote Rho activation through RhoGEF recruitment to the plasma membrane. The activated Rho then recruits the RlucII-tagged effector (PKN) to the PM. Rho activity is monitored using the BRET between RlucII and a membrane-bound rGFP. The Rho binding domain of PKN1 was tagged with RlucII (BRET donor) to monitor its recruitment to the plasma membrane using enhanced bystander BRET with rGFP-CAAX (krAS). To validate PKN recruitment by TPαR, HEK 293 cells were transfected in suspension with 10 ng of HA-β1AR and 1 ng of PKN-RlucII and 300 ng of CAAX-GFP. Prolume purple (1 μM) was added for 6 min and BRET was measured following injection of isoproterenol (1 μM) for 30 sec at 37 °C. To confirm specificity of Rho activation, HEK 293 cells were co-transfected with or without constitutively active RhoA mutant Q63A (50 ng per row of a 96-well plate). To validate the effect of Go12q/Go13 pathway on PKN recruitment to the plasma membrane, EE-tagged versions of Go12q, Go13q, and Go12q/Go13q CAM mutants (Q231L and Q226L, respectively) (10 ng) were transfected along with 100 ng of TPαR, 0.5 ng of PKN-RlucII and 300 ng of CAAX-GFP per row of a 96-well plate. Cells were stimulated for 6 min with either vehicle or U46619 (100 nM), and BRET values were collected using Prolume purple (1 μM final) as a substrate.

β-arrestin recruitment to the receptor: A BRET-based biosensor composed of hβ-arrestin2-RlucII and β1AR-GFP10 was used to monitor β-arrestin recruitment to the receptor. HEK 293 cells were transfected with 60 ng of hβ-arrestin2-RlucII and 1 μg of β1AR-GFP10. For concentration-response experiments, BRET values were monitored 10 min after agonist addition.

p115-CAAX-based inhibitor of G protein-mediated Rho activation. p115-CAAX is composed of the G protein binding domains (rGGS) of p115RhoGEF, targeted to the plasma membrane using the prenylated polybasic sequence from krAS. Upon receptor stimulation, p115-CAAX is recruited to activated G12 or G13, preventing recruitment of WT RhoGEF and thus activation of Rho. The rGGS domain is known to promote GTPase activity, further inhibiting G protein-signal transduction. To validate p115-CAAX as an inhibitor of G12/G13 pathway, HEK 293 cells were transfected with HA-TPαR (10 ng), PKN-RlucII (1 ng) and rGFP-CAAX (300 ng) along with p115-CAAX or ssDNA (mock). Cells were pre-treated with YM254890 or vehicle for 30 min at 37 °C and stimulated with TPαR agonist U46619 (100 nM) or vehicle for 6 min. For calcium mobilization experiments, HEK 293 cells were transfected with 500 ng of Obelin biosensor, 10 ng of HA-β1AR or HA-β2AR and 20 ng of p115-CAAX. Kinetic data for isoproterenol (1 μM) and A23187 (5 μM) were collected for 30 sec at 37 °C, with an integration time of 0.5 sec. To assess the effect of p115-CAAX on G12/G13 signalling, cells were transfected with 10 ng of receptor, 5 ng of G12q/G13q-RlucII, 100 ng of G13WT, 200 ng of GFP10-G13q, and 20 ng of p115-CAAX. BRET values were collected after 6 min of agonist stimulation (TPαR: U46619, D4R: dopamine) at 37 °C and addition of Prolume purple. The influence of p115-CAAX on cAMP response from endogenous β1AR, β2AR or overexpressed β1AR (10 ng) was assessed using EPAC biosensor (25 ng). BRET values were collected after 10 min of isoproterenol stimulation and addition of coelenterazine 400a, as described in calcium transfection (see below).

BRET experiments. BRET was in general performed as previously described. 48 h after transfection, cells were washed once with PBS and incubated for 1 h at 37 °C in Tyrode’s-HEPES buffer (137 mM NaCl, 0.9 mM KCl, 1 mM MgCl2, 11.9 mM NaHCO3, 5.5 mM glucose, 3.6 mM NaH2PO4, 25 mM HEPES, and 1 mM CaCl2, pH 7.4). The expression levels of the energy acceptor GFP10-tagged proteins were measured as total fluorescence using a FlexStation II microplate reader (Molecular Devices, Sunnyvale, CA, USA) with excitation at 400 nm and emission at 500 nm. Before βAR activation, cells were exposed to ICI 118,551 (10 nM) for 30 min prior to the experiment in order to inhibit βAR activity. For concentration-response experiments, cells were treated, with or without ligands, for the indicated times, and BRET was measured using a TriStar2 LB 942 Multidetection Microplate Reader (Berthold Technologies), equipped with a BRET400-GFP2/10 filter set (acceptor, 515 ± 20 nm; and donor, 400 ± 70 nm filters), 5 min after the addition of 2.5 μM of coelenterazine 400a. Absolute BRET signals (BRET) were derived from emissions detected with the energy acceptor filter divided by emission detected using the energy donor filter, while netBRET signals were obtained by subtracting BRET signals obtained in cells expressing the Rluc-fused donor constructs alone. ΔBRET was calculated by subtracting ligand-induced BRET from vehicle BRET. For kinetic experiments, cells were preincubated with coelenterazine 400a for 50 min, followed by readings for the indicated times, following addition of drugs. For G12 or G13, titration and concentration-response curves, 48 h post-transfection, wells were washed once with Kreb’s/HEPES buffer (146 mM NaCl, 4.2 mM KCl, 0.5 mM MgCl2, 1 mM CaCl2, 5.9 mM Glucose and 10 mM HEPES pH 7.4) and 80 μl of Kreb’s/HEPES buffer was added and plates left for 2–3 h at 37 °C. Then, 10 nM ICI 118,551 was added and plates left another 30 min at 37 °C to block endogenous βAR. Finally, agonists were added and BRET assessed similarly as described above, using a FLUOstar Optima (BMG) equipped with BRET2 filter set (410 nm/515 nm). Saturation assays were performed initially to determine optimal donor to acceptor ratios for kinetic experiments.
and concentration–response curves and read 1 to 3 minutes after agonist addition (concentration 1 mM isoproterenol). Kinetic measurements were performed 48 h post-transfection, 5 minutes after addition of coelenterazine 400a (2.5 µM) or Prolume purple (1 µM, 6 min).

**Calcium mobilization.** An obelin biosensor was used as a calcium reporter as described previously. Stable HA-β1AR HEK 293 cells were transfected in suspension with 500 ng of WT obelin-pLVXi2H per row. For experiments performed in parental and cells lacking Gαs proteins (ΔGs), cells were transiently transfected with 100 ng of receptor and WT obelin. 48 h after transfection, cells were washed once with Tyrode’s-HEPES buffer and incubated with the obelin substrate, coelenterazine cp (1 µM; Biotium) for ~2 h in the dark. For concentration-response experiments, increasing concentrations of agonists, diluted in Tyrode’s buffer, were injected into the wells and luminescence was measured using a SpectraMax L (Molecular Devices). Kinetics of activation were determined for each ligand concentration for 60 s and concentration-response curves were determined from the area under the curve (AUC). For Gαs complementation experiments, HEK 293 T parental or cells lacking Gαs were transfected with 10 ng of β1 or β2AR, 500 ng of obelin, in the presence or absence of 10 ng of Gαs. Luminescence was measured using a Mithras LB940 microplate reader.

**Cell surface ELISA.** Parental HEK 293 cells or cells lacking Gαs were transfected with HA-β1AR, HA-β2AR or HA-TPαR. 48 h after transfection cells were washed with PBS and fixed with 3% paraformaldehyde for 10 min at RT. Cells were labelled with mouse anti–HA-HRP antibody (3F10; 1:2000) for 1 h at RT in Wash B buffer (PBS supplemented with 0.5% BSA), followed by extensive washing (3 × 10 min). Vybrant DyeCycle Orange stain was added for 30 min at a final concentration of 10 µM at RT. Vybrant fluorescence was measured with excitation at 519 nm and emission at 563 nm using a FlexStationII microplate reader (Molecular Devices, Sunnyvale, CA, USA) to control for the number of cells/well. Total luminescence was measured 2 min after the addition of the HRP substrate Western lightning plus ECL using a Mithras LB940 microplate reader. Receptor cell surface expression was calculated as ratio of total luminescence to vibrant fluorescence.

**Data analysis.** Concentration response curves describing ligand responses by different ligands were analyzed with Graphpad Prismv6 (GraphPad Software, La Jolla, CA), using built-in 3 or 4 parameter logistic equations to obtain independent pEC50 and maximal response values for different receptor-biosensor pairs:

\[
y = a + \frac{b-a}{1 + 10^{\log EC50 - x}} \times c
\]

where:
- y is the measured response;
- a is the minimal asymptote,
- b-a is maximal response and
- c is the slope.

Data were also fit with the operational model of Black and Leff using a set of equations kindly provided by Dr. Arthur Christopoulos. These equations were introduced into Graphpad Prism6:

\[
A = 10^x
\]

\[
\text{operate 1} = \left(1 + \frac{A}{(10^{\log R})} \times A\right)^p \text{(used to fit full agonists)}
\]

\[
\text{operate 2} = \left(1 + \frac{A}{(10^{\log K_A})} \times A\right)^p \text{(used to fit partial agonists)}
\]

- Full agonist = basal + (Emax−basal)/(1 + operate1)
- Partial agonist = basal + (Emax−basal)/(1 + operate2)
- n → slope of the function which links occupancy to response
- Emax → maximal response of the system
- KA → functional affinity (partial agonists).

A one-phase exponential decay was used to calculate the half-life in kinetic experiments. Statistical significance of ligand-induced changes at the different biosensors was established using one-way ANOVA to reveal concentration effects. pEC50 and maximal responses of different ligands were compared to corresponding isoproterenol values by means of one-way ANOVA followed by post-hoc Dunnett test. Specific details on statistical comparisons are provided in legends of Figures and Tables.

**Data availability**

The authors declare that all data supporting the findings in this study are presented within the article and its associated Supplementary Information Files. These are available from the corresponding authors upon request. Our biosensors are licensed to Domain Therapeutics for commercial purposes but are freely available to the academic community.

Received: 4 September 2019; Accepted: 7 May 2020;
Published online: 29 May 2020
References

1. Kenakin, T. Signaling bias in drug discovery. Expert Opin Drug Discov 12, 321–333 (2017).
2. Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12, 205–16 (2013).
3. Kenakin, T. & Christopoulos, A. Measurements of ligand bias and functional affinity. Nat Rev Drug Discov 12, 483 (2013).
4. Smith, J. S., Lefkowitz, R. J. & Rajagopal, S. Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov 17, 243–260 (2018).
5. Stellaert, W., Dorn, J. F., van der Westhuizen, E., Audet, M. & Bouvier, M. Impedance responses reveal β2-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PLoS One 7, e29420 (2012).
6. van der Westhuizen, E. T., Breton, B., Christopoulos, A. & Bouvier, M. Quantification of Ligand Bias for Clinically Relevant β-adrenergic Receptor Ligands: Implications for Drug Toxicology. Mol Pharmacol 85, 492–509 (2014).
7. Baker, J. G., Hill, S. J. & Summers, R. J. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci 32, 227–34 (2011).
8. Galdandin, S. et al. Conformational rearrangements and signalling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the β1-adrenergic receptor. Mol Pharmacol 74, 162–72 (2008).
9. Kim, I. M. et al. β-blockers alpenroliden and cardevaldin stimulate β2-agonist-mediated EGRF transactivation. Proc Natl Acad Sci USA 105, 14555–60 (2008).
10. Noma, T. et al. β-arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117, 2445–58 (2007).
11. Wisler, J. W. et al. A unique mechanism of β-blocker action: cardevaldin stimulates β-arrestin signaling. Proc Natl Acad Sci USA 104, 16657–62 (2007).
12. Marinissen, M. J. & Gutkind, J. S. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22, 368–76 (2001).
13. Kenakin, T. Biased Receptor Signaling in Drug Discovery. Pharmacol Rev 71, 267–315 (2019).
14. Salapour, A. et al. BRET biosensors to study GPCR biology, pharmacology, and signal transduction. Front Endocrinol (Lausanne) 3, 105 (2012).
15. Sauliere, A. et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol 8, 622–30 (2012).
16. Masuo, I. et al. Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors. Sci Signal 8, ra123 (2015).
17. Namkung, Y. et al. Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors. Sci Signal 11(48), (2018).
18. Martin, R. D. et al. Receptor- and cellular compartment-specific activation of the cAMP/PKA pathway by β1-adrenergic and ETA endothelin receptors. Cell Signal 44, 43–50 (2018).
19. Milligan, G. & Inoue, A. Genome Editing Provides New Insights into Receptor-Controlled Signalling Pathways. Trends Pharmacol Sci 39, 481–493 (2018).
20. Stellaert, W. et al. Purinergic Receptor Transactivation by the β1-Adrenergic Receptor Increases Intracellular Ca(2+) in Nonexcitable Cells. Mol Pharmacol 91, 533–544 (2017).
21. Devost, D. et al. Conformational Profiling of the AT1 Angiotensin II Receptor Reveals Biased Agonism, G-Protein Coupling, and Cellular Context. J Biol Chem 292, 5443–5456 (2017).
22. Slaven, R. et al. Conformational biosensors reveal allosteric interactions between heterodimeric AT1 angiotensin and prostaglandin F2α receptors. J Biol Chem 292, 12139–12152 (2017).
23. Namkung, Y. et al. Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET. Nat Commun 7, 12178 (2016).
24. Mende, F. et al. Translating biased signaling in the ghrelin receptor system into differential in vivo functions. Nat Sci Pharmacol Sci 115, E10255–E10264 (2018).
25. Gales, C. et al. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol 13, 778–86 (2006).
26. Brule, C. et al. Biased signaling regulates the pleiotropic effects of the uterotonin II receptor to modulate its cellular behaviors. FASEB J 28, 5148–62 (2014).
27. Moller, D. et al. Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure. J Med Chem 60, 2908–2929 (2017).
28. Masri, B. et al. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105, 13656–61 (2008).
29. Leduc, M. et al. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther 331, 297–307 (2009).
30. Daaka, Y., Luttrell, L. M. & Lefkowitz, R. J. Switching of the coupling of the β1-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88–91 (1997).
31. Zhu, W., Zeng, X., Zheng, M. & Xiao, R. P. The enigma of β1-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly. Circ Res 97, 507–9 (2005).
32. Beattie, D. et al. An investigation into the structure-activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol. Bioorg Med Chem Lett 22, 6280–5 (2012).
33. Battram, C. et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quino-lin-2-0 ne (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317, 762–70 (2006).
34. Mackenzie, A. E. et al. Receptor selectivity between the G proteins Go12 and Go13 is defined by a single leucine-to-isoleucine variation. FASEB J 33, 5005–5017 (2019).
35. Zhang, Z., Li, F. & Lefkowitz, R. J. The Gq and G12 families of heterotrimeric G proteins report functional selectivity. Mol Pharmacol 75, 235–41 (2009).
36. Gratacap, M. P., Payrastre, B., Nieswandt, B. & Offermanns, S. Differential regulation of Rho and Rac through heterotrimeric G proteins and cyclic nucleotides. J Biol Chem 276, 47906–13 (2001).
37. Bhattacharyya, R. & Wedegaertner, P. B. Characterization of Go13-dependent plasma membrane recruitment of p115RhoGEF. Biochem J 371, 709–20 (2003).
38. Pan, Z. K. et al. Role of the Rho GTPase in bradykinin-stimulated nuclear factor B activation and IL-1β gene expression in cultured human epithelial cells. J Immunol 160, 3038–45 (1998).
39. Inoue, A. et al. Illuminating G-Protein-Coupling Selectivity of GPCRs. Cell (2019).
40. Malikova, N. P., Burakova, L. P., Markova, S. V. & Vyotski, E. S. Characterization of hydromedusan Ca(2+)-regulated proteinophores as a tool for measurement of Ca(2+)concentration. Anal Bioanal Chem 406, 5715–26 (2014).
41. Angers, S. et al. Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 97, 3684–9 (2000).
42. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. & Novick, S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3, 193–203 (2012).
43. Ho, J. H. et al. G protein signaling-biased agonism at the \( \kappa \) opioid receptor is maintained in striatal neurons. Sci Signal 11(2018).

44. Zhang, Z. S., Cheng, H. J., Ukai, T., Tachibana, H. & Cheng, C. P. Enhanced cardiac L-type calcium current response to \( \beta_2 \)-adrenergic stimulation in heart failure. J Pharmacol Exp Ther 298, 188–96 (2001).

45. Christ, T., Galindo-Tovar, A., Thoms, M., Ravens, U. & Kaumann, A. J. Inotropy and L-type Ca\(^{2+}\) current, activated by \( \beta_1 \)- and \( \beta_2 \)-adrenoceptors, are differentially controlled by phosphodiesterases 3 and 4 in rat heart. Br J Pharmacol 156, 62–83 (2009).

46. Benita, J. P., Alves, J. L. & Gomez, A. M. L-type Ca\(^{2+}\) current in ventricular cardiomyocytes. J Mol Cell Cardiol 48, 26–36 (2010).

47. Henstridge, C. M. et al. The GPR55 ligand L-\( \alpha \)-lysophosphatidylinositol promotes RhoA-dependent Ca\(^{2+}\) signaling and NFAT activation. FASEB J 23, 183–93 (2009).

48. Lauckner, J. E. et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105, 2699–704 (2008).

49. Wong, Y. H., Conklin, B. R. & Bourne, H. R. Gz-mediated hormonal inhibition of cyclic AMP accumulation. Science 255, 339–42 (1992).

50. Yang, J. et al. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci USA 97, 9984–9 (2000).

51. Armando, S. et al. The chemokine CXC4 and CC2 receptors form homo- and heterooligomers that can engage their signaling G-protein effectors and betaarrestin. FASEB J 28, 4509–23 (2014).

52. Carr, R. III et al. Development and characterization of pepducins as Gs-biased allosteric agonists. J Biol Chem 289, 35668–84 (2014).

53. Ponsioen, B. et al. Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep. 5, 1176–1180 (2004).

54. Campbell, A. K. & Dormer, R. L. Studies on free calcium inside pigeon erythrocyte ‘ghosts’ by using the calcium-activated luminescent protein, obelin. Biochem Soc Trans 3, 709–11 (1975).

55. Quoyer, J. et al. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci USA 110, E5088–97 (2013).

56. Black, J. W. & Leff, P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220, 141–62 (1983).

Acknowledgements
This work was supported by grants from the Canadian Institute for Health Research (CIHR) [MOP11215] and [FDN148431] to M.B. and [PJ]T159687] to T.E.H. M.B. holds a Canada Research Chair in Signal Transduction and Molecular Pharmacology.

Author contributions
C.L.G., S.A.L., G.P., M.B. and T.E.H. designed the study. A.I. Y.S and J.A. generated and characterized the G\( \alpha \)s KO line using CRISPR/Cas9. D.D., V.L., Y.N, J.-M.L., M.A, M.H. R.D.M. and B.B. performed the experiments as well as the analysis of the data. D.D, V.L. M.L. C.L.G, J.C.T., S.A.L., G.P., M.B. and T.E.H. interpreted the data and wrote the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65636-3.

Correspondence and requests for materials should be addressed to M.B. or T.E.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020